|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Product | |||||
| Grant and Contract | |||||
| Total revenue | |||||
| Cost of revenue | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Sales and marketing | |||||
| Armor exit costs | |||||
| Reduction in force | |||||
| Grant and contract expenses | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expenses): | |||||
| Interest expense | |||||
| Interest income | |||||
| Gain (loss) on the disposal of assets | |||||
| Change in fair value of derivative liabilities | |||||
| Offering costs of derivative liabilities | |||||
| Other income (expense) | |||||
| Total other income (expense), net | |||||
| Net loss before income taxes | |||||
| Net loss | |||||
| Deemed dividend related to beneficial conversion feature on convertible preferred stock | |||||
| Deemed dividend related to warrant inducement | |||||
| Net loss attributable to common stockholders | |||||
| Net loss per share – basic and diluted | |||||
| Basic – net loss | |||||
| Basic – deemed dividend and accretion of a discount on conversion of preferred stock | |||||
| Basic – deemed dividend related to warrant inducement | |||||
| Basic – attributable to common stockholders | |||||
| Diluted – net loss | |||||
| Diluted - deemed dividend and accretion of a discount on conversion of preferred stock | |||||
| Diluted - deemed dividend related to warrant inducement | |||||
| Diluted – attributable to common stockholders | |||||
| Weighted average common shares outstanding: | |||||
| Basic | |||||
| Diluted | |||||
Loading...